Is LXRX or MBRX more undervalued in 2026?

CirclFi compares Lexicon Pharmaceuticals, Inc. (LXRX) and Moleculin Biotech, Inc. (MBRX) using 13 institutional-grade valuation models. LXRX has a Quality of Company score of 7.4/10 while MBRX scores 4.3/10.

Which is a better buy — LXRX or MBRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do LXRX and MBRX valuations compare?

LXRX at $2.18 and MBRX at $2.79 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

LXRX vs MBRX Valuation Comparison 2026 — Intrinsic Value Analysis

LXRX

Pharmaceutical Preparations

Lexicon Pharmaceuticals, Inc.

Quality

7.4

out of 10

Value Trap

SAFE

Price

$2.18

Last close

Models

11/13

Active

MBRX

Pharmaceutical Preparations

Moleculin Biotech, Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$2.79

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	LXRX Fair Value	LXRX Upside	MBRX Fair Value	MBRX Upside
Bayesian DCF	Intrinsic	$0.59	-72.8%	$1.66	-40.5%
Earnings Power Value	Intrinsic	$0.29	-81.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.18	-91.9%	$7.87	+182.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for LXRX vs MBRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LXRX vs MBRX — Which Stock Is More Undervalued?

LXRX scores higher with a 7.4/10 quality rating vs MBRX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Lexicon Pharmaceuticals, Inc. (LXRX) and Moleculin Biotech, Inc. (MBRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LXRX currently trades at $2.18 with a QOC of 7.4/10, while MBRX trades at $2.79 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).